Analytical Data
-
Gene name
ABL1
- Application
-
Alternative Names
ABL1；ABL；JTK7；Tyrosine-Protein kinase ABL1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P00519
-
Expression Region
27-1130aa
-
AA Sequence
EALQRPVASD FEPQGLSEAA RWNSKENLLA GPSENDPNLF VALYDFVASG DNTLSITKGE KLRVLGYNHN GEWCEAQTKN GQGWVPSNYI TPVNSLEKHS WYHGPVSRNA AEYLLSSGIN GSFLVRESES SPGQRSISLR YEGRVYHYRI NTASDGKLYV SSESRFNTLA ELVHHHSTVA DGLITTLHYP APKRNKPTVY GVSPNYDKWE MERTDITMKH KLGEGHFGEV YEGVWKKYSL TVAVKTLKED TMEVEEFLKE AAVMKEIKHP NLVQLLGVCT REPPFYIITE FMTYGNLLDY LRECNRQEVN AVVLLYMATQ ISSAMEYLEK KNFIHRDLAA RNCLVGENHL VKVADFGLSR LMTGDTYTAH AGAKFPIKWT APESLAYNKF SIKSDVWAFG VLLWEIATYG MSPYPGIDLS QVYELLEKDY RMERPEGCPE KVYELMRACW QWNPSDRPSF AEIHQAFETM FQESSISDEV EKELGKQGVR GAVSTLLQAP ELPTKTRTSR RAAEHRDTTD VPEMPHSKGQ GESDPLDHEP AVSPLLPRKE RGPPEGGLNE DERLLPKDKK TNLFSALIKK KKKTAPTPPK RSSSFREMDG QPERRGAGEE EGRDISNGAL AFTPLDTADP AKSPKPSNGA GVPNGALRES GGSGFRSPHL WKKSSTLTSS RLATGEEEGG GSSSKRFLRS CSASCVPHGA KDTEWRSVTL PRDLQSTGRQ FDSSTFGGHK SEKPALPRKR AGENRSDQVT RGTVTPPPRL VKKNEEAADE VFKDIMESSP GSSPPNLTPK PLRRQVTVAP ASGLPHKEEA GKGSALGTPA AAEPVTPTSK AGSGAPGGTS KGPAEESRVR RHKHSSESPG RDKGKLSRLK PAPPPPPAAS AGKAGGKPSQ SPSQEAAGEA VLGAKTKATS LVDAVNSDAA KPSQPGEGLK KPVLPATPKP QSAKPSGTPI SPAPVPSTLP SASSALAGDQ PSSTAFIPLI STRVSLRKTR QPPERIASGA ITKGVVLDST EALCLAISRN SEQMASHSAV LEAGKNLYTF CVSYVDSIQQ MRNKFAFREA INKLENNLRE LQICPATAGS GPAATQDFSK LLSSVKEISD IVQR
-
Molecular Weight
135 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ABL1 is a key proto-oncogene that encodes a non-receptor tyrosine kinase, playing a significant role in cellular processes such as cell proliferation, differentiation, and apoptosis. The gene has garnered considerable attention due to its involvement in various cancers, particularly in Philadelphia chromosome-positive chronic myeloid leukemia (CML), where the BCR-ABL1 fusion protein exhibits constitutive kinase activity, leading to uncontrolled cell growth. Research on ABL1 recombinant protein is crucial for understanding its role in oncogenesis and developing targeted therapies. The study of ABL1 has progressed significantly since the discovery of its oncogenic fusion protein in the 1980s. Continued investigation into ABL1 undergoes to reveal its biochemical properties and interactions within signaling pathways, offering insights into potential therapeutic interventions. Moreover, the production and characterization of ABL1 recombinant proteins allow researchers to probe the structural and functional aspects of its kinase activity, providing a platform for drug discovery and the development of ABL1 inhibitors, which can effectively target BCR-ABL1-driven malignancies. This research not only elucidates its pathological significance but also enhances our understanding of normal cellular functions regulated by ABL1, paving the way for innovative cancer treatments and personalized medicine approaches.
